Comparison
Petrelintide vs. VK2735
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
no data
Molecular weight
no data
no data
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Petrelintide
As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.
VK2735
VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
1
of which in humans
1
1
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Petrelintide and VK2735?
- Petrelintide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Petrelintide or VK2735?
- The highest available evidence level is "Human RCT" for Petrelintide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Petrelintide and VK2735 in Germany and the United States?
- Germany: Petrelintide — Unapproved, VK2735 — Unapproved. United States: Petrelintide — Unapproved, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.